FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229451231> ?p ?o ?g. }

• W4229451231 endingPage "181" @default.
• W4229451231 startingPage "166" @default.
• W4229451231 abstract "Effective treatments for hematologic malignancies include therapies that target tyrosine kinase (TK) signaling pathways. Tumor lysis syndrome (TLS) is an oncologic emergency that can occur due to rapid turnover following the initiation of treatments for hematologic malignancy. The incidence of TLS is under-reported and it is unclear as to whether TK inhibitors (TKIs) are associated with TLS.To conduct a systematic review to determine the incidence of TLS with TKIs.A search was performed using EMBASE, MEDLINE, and Web of Science electronic databases, as well as a manual search of the American Society of Hematology and American Society of Clinical Oncology abstract databases. Keywords included: tumor lysis syndrome, tyrosine kinase inhibitors, lymphoma, and leukemia.We identified a total of 57 publications that commented on the incidence of TLS with TKIs for hematologic malignancy. Thirty-nine of those publications reported TLS as an adverse event. TLS was described as an adverse event among essentially all the subclasses of TKIs that are used to manage hematologic malignancies.The overall number of articles commenting on TLS as an adverse event is sparse and there needs to be more transparency regarding the incidence of TLS when employing newer targeted therapies. Physicians should consider the risk of TLS on an individual basis and the added risk of TLS when using TKIs to treat hematologic malignancy." @default.
• W4229451231 created "2022-05-11" @default.
• W4229451231 creator A5003263508 @default.
• W4229451231 creator A5031238472 @default.
• W4229451231 creator A5041757623 @default.
• W4229451231 creator A5077818820 @default.
• W4229451231 creator A5079142034 @default.
• W4229451231 creator A5090405846 @default.
• W4229451231 date "2022-05-24" @default.
• W4229451231 modified "2023-10-10" @default.
• W4229451231 title "Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review" @default.
• W4229451231 cites W1740327132 @default.
• W4229451231 cites W1881553659 @default.
• W4229451231 cites W1964663305 @default.
• W4229451231 cites W1974059206 @default.
• W4229451231 cites W1984436001 @default.
• W4229451231 cites W2001339027 @default.
• W4229451231 cites W2017129631 @default.
• W4229451231 cites W2038918176 @default.
• W4229451231 cites W2039339378 @default.
• W4229451231 cites W2046889760 @default.
• W4229451231 cites W2057528076 @default.
• W4229451231 cites W2058786064 @default.
• W4229451231 cites W2065851457 @default.
• W4229451231 cites W206701898 @default.
• W4229451231 cites W2091428072 @default.
• W4229451231 cites W2097177625 @default.
• W4229451231 cites W2116667574 @default.
• W4229451231 cites W2120421624 @default.
• W4229451231 cites W2134138207 @default.
• W4229451231 cites W2138300654 @default.
• W4229451231 cites W2141234027 @default.
• W4229451231 cites W2155356776 @default.
• W4229451231 cites W2224095737 @default.
• W4229451231 cites W2239147471 @default.
• W4229451231 cites W2312804644 @default.
• W4229451231 cites W2335967795 @default.
• W4229451231 cites W2344488712 @default.
• W4229451231 cites W2385009615 @default.
• W4229451231 cites W2654449699 @default.
• W4229451231 cites W2738155864 @default.
• W4229451231 cites W2743252677 @default.
• W4229451231 cites W2750813742 @default.
• W4229451231 cites W2755389242 @default.
• W4229451231 cites W2765857600 @default.
• W4229451231 cites W2774522106 @default.
• W4229451231 cites W2783739433 @default.
• W4229451231 cites W2795301499 @default.
• W4229451231 cites W2795473913 @default.
• W4229451231 cites W2808764596 @default.
• W4229451231 cites W2810959879 @default.
• W4229451231 cites W2883790493 @default.
• W4229451231 cites W2897902093 @default.
• W4229451231 cites W2900694112 @default.
• W4229451231 cites W2904401218 @default.
• W4229451231 cites W2907337505 @default.
• W4229451231 cites W2946882253 @default.
• W4229451231 cites W2962038803 @default.
• W4229451231 cites W2968566880 @default.
• W4229451231 cites W2972190030 @default.
• W4229451231 cites W2979370323 @default.
• W4229451231 cites W2987080466 @default.
• W4229451231 cites W2989817045 @default.
• W4229451231 cites W2995713331 @default.
• W4229451231 cites W2999980976 @default.
• W4229451231 cites W3005942772 @default.
• W4229451231 cites W3011469361 @default.
• W4229451231 cites W3012011926 @default.
• W4229451231 cites W3012614383 @default.
• W4229451231 cites W3012874730 @default.
• W4229451231 cites W3045452677 @default.
• W4229451231 cites W3046825703 @default.
• W4229451231 cites W3049430822 @default.
• W4229451231 cites W3089478032 @default.
• W4229451231 cites W3091127361 @default.
• W4229451231 cites W3095485612 @default.
• W4229451231 cites W3137578141 @default.
• W4229451231 cites W3151974300 @default.
• W4229451231 cites W3212343548 @default.
• W4229451231 cites W3213382238 @default.
• W4229451231 cites W3213415996 @default.
• W4229451231 cites W3216874257 @default.
• W4229451231 cites W4242820529 @default.
• W4229451231 doi "https://doi.org/10.1111/ejh.13786" @default.
• W4229451231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35531791" @default.
• W4229451231 hasPublicationYear "2022" @default.
• W4229451231 type Work @default.
• W4229451231 citedByCount "2" @default.
• W4229451231 countsByYear W42294512312023 @default.
• W4229451231 crossrefType "journal-article" @default.
• W4229451231 hasAuthorship W4229451231A5003263508 @default.
• W4229451231 hasAuthorship W4229451231A5031238472 @default.
• W4229451231 hasAuthorship W4229451231A5041757623 @default.
• W4229451231 hasAuthorship W4229451231A5077818820 @default.
• W4229451231 hasAuthorship W4229451231A5079142034 @default.
• W4229451231 hasAuthorship W4229451231A5090405846 @default.
• W4229451231 hasConcept C120665830 @default.
• W4229451231 hasConcept C121332964 @default.

• next